Pacira BioSciences' Income from Continuing Operations rose 10378.63% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 12362.81%. This contributed to the annual value of -$99.6 million for FY2024, which is 33730.19% down from last year.
Per Pacira BioSciences' latest filing, its Income from Continuing Operations stood at $5.4 million for Q3 2025, which was up 10378.63% from -$4.8 million recorded in Q2 2025.
Over the past 5 years, Pacira BioSciences' Income from Continuing Operations peaked at $25.8 million during Q2 2023, and registered a low of -$143.5 million during Q3 2024.
Moreover, its 5-year median value for Income from Continuing Operations was $9.0 million (2024), whereas its average is $296631.6.
As far as peak fluctuations go, Pacira BioSciences' Income from Continuing Operations skyrocketed by 166681.1% in 2023, and later crashed by 142129.31% in 2024.
Over the past 5 years, Pacira BioSciences' Income from Continuing Operations (Quarter) stood at -$5.1 million in 2021, then plummeted by 96.92% to -$10.1 million in 2022, then soared by 346.19% to $24.9 million in 2023, then tumbled by 35.5% to $16.0 million in 2024, then crashed by 66.14% to $5.4 million in 2025.
Its last three reported values are $5.4 million in Q3 2025, -$4.8 million for Q2 2025, and $4.8 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value